A scientific research team from John Hopkins University (Baltimore, MD) has come up with a very smart way of delivering herpes and other treatments topically.
Certain surfaces of the body, like the eyes, the lungs, and the genital tract are protected by a mucous layer which is nature’s way of keeping out many infections. But the downside of this natural protection is that when medicines are administered topically to mucosal surfaces, the layer of mucus also prevents the drug from penetrating adequately.
Nanoparticles within a conventional topically applied vaginal gel, for example, will adhere to the mucous coating of the vaginal walls and although some of the active ingredients may work, the mucous is constantly replaced, so that most of the drug is effectively “washed away” and therefore ineffective.
The John Hopkins Team has developed mucous penetrating (nano) particles (MPPs) that mimic the effect of viruses such as HSV-2, which can penetrate the mucous walls easily. Laboratory tests using this innovative technology were carried out on herpes infected mice.
Read Also:- Are you Suffering Bowel Problems? You Could Have Coeliac Disease
Researcher and director of John Hopkins Center for Nanomedicine, Justin Hanes explained that as the means of delivering drugs through the mucous membranes is so effective, a ten-fold weaker drug dose was able to “continue to supply the drug for at least a day and provide nearly 100 percent coverage of the mucosal surface of the vagina and ectocervix” in the mice.
Fellow researcher Laura Ensign commented: “We’ve seen that mucus-penetrating particles are safe for mice. Our next step will be to prove that they are safe for humans.”
She added that the technology could lead to a once-daily treatment for sexually transmitted diseases, contraception and the treatment of Cervo-vaginal disorders.
British Herpes Drug Receives Limited FDA Approval
Foscavir (foscarnet sodium injection), which inhibits the replication of HSV1 and HSV2 herpes virus in vitro, has been given limited approval by the FDA (US Food and Drug Administration).
Approval for the drug is restricted to the treatment of immunocompromised patients with HIV and acyclovir-resistant mucocutaneous HSV infections as an emergency measure.
The drug comes with a warning of kidney toxicity, with renal function monitoring and hydration a necessity. There is a long list of common side-effects with this drug treatment.
Unlike drugs, natural remedies have no side effects as mentioned in Herpes Blitz Protocol reviews from people who tested it.
It should be stressed that this drug is only for use in the case of patients who are severely ill and under constant medical supervision.
British owned Clinigen acquired the rights to Foscarnet sodium from AstraZeneca in March. US distribution rights belong to Illinois-based Hospira.
